期刊文献+

静脉使用蔗糖铁治疗老年人射血分数保留心力衰竭合并铁缺乏的疗效观察 被引量:2

Effect of intravenous iron sucrose in the treatment of elderly heart failure with preserved ejection fraction and iron deficiency
原文传递
导出
摘要 目的观察老年射血分数保留心力衰竭(HFpEF)合并铁缺乏(ID)患者静脉使用蔗糖铁治疗能否改善心功能。方法选取安阳地区医院心内科2016年6~12月治疗的老年HFpEF合并ID患者(年龄≥65岁)89例,采用随机数字表法分为治疗组45例和对照组44例,两组患者均给予常规抗心力衰竭药物治疗。治疗组在常规药物治疗的基础上静脉注射蔗糖铁注射液200mg,每周1次。两组患者均每月检验血清铁蛋白(SF)、转铁蛋白饱和度(TS)及血红蛋白(Hb)水平,两组患者均于0个月、6个月行心脏彩色多普勒超声、6分钟步行试验(6MWT)、静脉血氨基端脑钠肽前体(NT-proBNP)检查。观察两组患者治疗6个月前后左心房内径(LAD)、二尖瓣早期血流速度/舒张晚期血流速度比值(E/A)、左心室舒张末期内径(LVEDD)、6MWT、NT—proBNP等心功能指标的变化。结果治疗前,两组sF、TS、Hb、LAD、LVEDD、NT—proBNP、E/A、6MWT差异均无统计学意义(均P〉0.05)。治疗后,治疗组SF、TS、Hb分别为(244.23±1.69)μg/L、(26.17±1.15)%、(132.08±3.15)g/L,均高于对照组的(30.70±7.11)μg/L、(10.10±9.31)%、(111.0±0.08)g/L,差异均有统计学意义(t=32.661、9.881、25.123,均P〈0.05);治疗组LVEDD、LAD、NT—proBNP分别为(50.70±7.11)mm、(32.17±0.35)mm、(1077.17±9.35)ng/L,均低于对照组的(54.23±1.69)mm、(36.10±3.31)mm、(1636.10±0.31)ng/L,差异均有统计学意义(t=8.123、6.984、11.484,均P〈0.05);治疗组E/A、6MWT分别为(1.18±0.15)、(414.23±5.69)m,均高于对照组的(0.97±0.33)、(350.70±7.11)m,差异均有统计学意义(t=4.168、12.123,P〈0.05)。结论静脉使用蔗糖铁治疗可改善老年HFpEF合并ID患者心功能。 Objective To discuss the effect of intravenous iron sucrose in the treatment of elderly heart failure with preserved ejection fraction(HFpEF) and iron deficiency(ID). Methods From June 2016 to December2016,89 elderly patients with HFpEF and ID( age ≥ 65 years old) in Anyang Prefecture Hospital were randomly divided into treatment group ( n = 45 ) and control group ( n = 44). The two groups were treated with routine drugs for heart failure. The treatment group was intravenously given iron sucrose injection once a week on the basis of conventional treatment. The SF,TS and Hb were tested in the two groups every month. The echocardiography Doppler, six minutes walk test (6MWT) and N- terminal probrain natriuretic peptide( NT- proBNP) before and after experiment were examined in two groups. The changes of left artial diameter( LAD), the mitral valve early flow velocitye/the late diastolic blood flow velocity ratio(E/A) ,left ventricular end diastolic (LVEDD), 6MWT, NT - proBNP were observed in the two groups before and after six months treatment. Results Before treatment, the levels of ST, TS, Hb, LAD, LVEDD, NT - proB- NP,E/A, 6MWT in the two groups had no statistically significant differences (P 〉 0. 05 ). After treatment for 6 months,the levels of ST,TS and Hb in the treatment group were significantly higher than those in the control group [ (244.23 ± 1.69.) μg/L vs. (30.70 ±7.11) μg/L, (26.17 ±1.15)% vs. (10.10 ±9.31)% ,(132.08 ±3.15) g/L vs. (111.0 ±0.08) g/L] (t =32.661,9. 881,25. 123 ,all P 〈0.05). The levels of LVEDD,LAD and NT - proBNP of the treatment group were significantly lower than those of the control group [ ( 50.70 ± 7.11 ) mm vs. ( 54.23 ± 1.69) mm,(32.17 ±0.35)mm vs. (36.10 ±3.31)mm, (1077.17 ±9.35) ng/L vs. (1636.10 ±0.31) ng/L] (t =8. 123,6.984,11. 484, all P 〈 0.05 ). The levels of E/A ,6MWT of the treatment group were significantly higher than those of the control group[ ( 1.18 ±0. 15) vs. (0.97 ± 0.33 ), (414.23 ± 5.69) m vs (350.70 ± 7.11 ) m ] ( t = 4. 168,12. 123, all P 〈 0.05 ). Conclusion Intravenous iron sucrose can improve cardiac function in the elderly patients with HFpEF and ID.
作者 葛慧敏 Ge Huimin(Deparment of Cardiology,Anyang Prefecture Hospital,Anyang,He'nan 455000,Chin)
出处 《中国基层医药》 CAS 2018年第14期1820-1823,共4页 Chinese Journal of Primary Medicine and Pharmacy
关键词 心力衰竭 每搏输出量 铁化合物 老年人 Heart failure Stroke volume Iron compounds Aged
  • 相关文献

参考文献7

二级参考文献112

  • 1曹雅旻,胡大一,吴彦,王宏宇.我国基层医院慢性心力衰竭主要原因的初步调查[J].中华内科杂志,2005,44(7):487-489. 被引量:29
  • 2Bueno H,Ross JS,Wang Y,et al.Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure,1993-2006.JAMA,2010,303-2141-2147.
  • 3Hernandez AF,Greiner MA,Fonarow GC,et al.Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure.JAMA,2010,303:1716-1722.
  • 4Velavan P,Khan NK,Goode K,et al.Predictors of short term mortality in heart failure-insights from the Euro Heart Failure survey.Int J Cardiol,2010,138:63-69.
  • 5Zile MR,Gaasch WH,Anand IS,et al.I-Preserve Investigators.Mode of death in patients with heart failure and a preserved ejection fraction:results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study(I-Preserve)trial.Circulation,2010,121:1393-1405.
  • 6Shah RV,Desai AS,Givertz MM.The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction:a systematic review and meta-analysis.J Card Fail,2010,16:260-267.
  • 7Lee DS,Ghosh N,Floras JS,et al.Association of blood pressure at hospital discharge with mortality in patients diagnosed with heart failure.Circ Heart Fail,2009,2:616-623.
  • 8Nbfiez J,Nufiez E,Fonarow GC,et al.Differential prognostic effect of systolic blood pressure on mortality according to leftventricular function in patients with acute heart failure.Eur J Heart Fail,2010,12:38-44.
  • 9Bowling CB,Pitt B,Ahmed MI,et al.Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease:findings from propensity-matched studies.Circ Heart Fail,2010,3:253-260.
  • 10Ekundayo OJ,Adamopoulos C,Ahmed MI,et al.Oral potassium supplement use and outcomes in chronic heart failure:a propensity-matched study.Int J Cardiol,2010,141:167-174.

共引文献4881

同被引文献36

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部